Association of SARS susceptibility with single nucleic acid polymorphisms of OASI and MxA genes: A case-control study

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  He, Jing ^a   Feng, Dan ^a   de Vlas, Sake J ^b   Wang, Hongwei ^a   Fontanet, Arnaud ^c   Zhang, Panhe ^a   Plancoulaine, Sabine ^d   Tang, Fang ^a   Zhan, Lin ^a   Yang, Hong ^a   Wang, Tianbao ^e   Richardus, Jan H ^b   Habbema, J Dik F ^b   Cao, Wuchun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; MYXOVIRUS RESISTANCE PROTEIN A;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GTP-BINDING PROTEINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 33747380255     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-106     Document Type: Article

References (29)

1. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300:1394-1399.
2. World Health Organization: Summary of probable SARS cases with onset of illness from I November 2002 to 31 July. [http:/www.who.int/csr/sars/].
3. Ashraf H: WHO declares Beijing to be free of SARS. Lancet 2003, 361:2212.
4. Lee A: Host and environment are key factors. J Epidemiol Community Health 2003, 57:770.
5. Ng MH, Lau KM, Li L, Cheng SH, Chan WY, Hui PK, Zee B, Leung CB, Sung JJ: Association of human-leukocyte-antigen class I (B*0703) and class II (DRBI*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis 2004, 190:515-518.
6. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, Chen PJ, Su YW, Lim KH, Tsai ZU, Lin RY, Lin RS, Huang CH: Association of HLA class I with severe acute respiratory syndrome corona-virus infection. BMC Med Genet 2003, 4:9.
7. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha le D, Ban VV, Ohashi J, Hijikata M, Matsushita I, Kawana A, Yanai H, Kirikae T, Kuratsuji T, Sasazuki T: ACE I polymorphism and progression of SARS. Biochem Biophys Res Commun 2004, 323:1124-1129.
8. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW: Treatment of SARS with human interferons. Lancet 2003, 362:293-294.
9. Enserink M: SARS treatment: Interferon shows promise in monkeys. Science 2004, 303:1273-1275.
10. Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H: Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 2004, 189:1164-1167.
11. Rebouillat D, Hovanessian AG: The human 2′,5′-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res 1999, 19:295-308.
12. Schwemmle M, Weining KC, Richter MF, Schumacher B, Staeheli P: Vesicular stomatitis virus transcription inhibited by purified MxA protein. Virology 1995, 206:545-554.
13. Landis H, Simon-Jodicke A, Kloti A, Di Paolo C, Schnorr JJ, Schneider-Schaulies S, Hefti HP, Pavlovic J: Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. J Virol 1998, 72:1516-1522.
14. Hefti HP, Frese M, Landis H, Di Paolo C, Aguzzi A, Haller O, Pavlovic J: Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections. J Virol 1999, 73:6984-6991.
15. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H: Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004, 11:271-276.
16. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC, Hill AV, Thursz MR: Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-I and PKR. Genes Immun 2003, 4:411-419.
17. Hamano E, Hijikata M, Itoyama S, Quy T, Phi NC, Long HT, Ha le D, Ban VV, Matsushita I, Yanai H, Kirikae F, Kirikae T, Kuratsuji T, Sasazuki T, Keicho N: Polymorphisms of interferon-inducible genes OAS-I and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun 2005, 329:1234-1239.
18. Ma HJ, Wang HW, Fang LQ, Jiang JF, Wei MT, Liu W, Zhao QM, Ma J, Cao WC: A case-control study on the risk factor s of sever e acute respiratory syndromes among health care workers. Chin J Epidemiol 2004, 25:741-744.
19. Pang XH, Liu DL, Gong XH, Xu FJ, Liu ZJ, Zhang Z, Wang XH, Jiao XR, Su LY, Gao GH: Study on the risk factors related to severe acute respiratory syndrome among close contactors in Beijing. Chin J Epidemiol 2004, 25:674-676.
20. Wang M, Du L, Zhou DH, Di B, Liu YF, Qin PZ, Wu XW, Chen XS, Qiu JC, Li ZR: Study on the epidemiology and measures for control on severe acute respiratory syndrome in Guangzhou city. Chin J Epidemiol 2003, 24:353-3757.
21. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubel V, Guenet JL, Despres P: A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/LI isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci U S A 2002, 99:11311-11316.
22. Lucas M, Mashimo T, Frenkiel MP, Simon-Chazottes; D, Montagutelli X, Ceccaldi PE, Guenet JL, Despres P: Infection of mouse neurones by West: Nile virus is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase Ib protein. Immunol Cell Biol 2003, 81:230-236.
23. Benech P, Mory Y, Revel M, Chebath J: Structure of two forms of the interferon-induced (2′-5′) oligo A synthetase of human cells based on cDNAs and gene sequences. EMBO J 1985, 4:2249-2256.
24. Aissouni Y, Perez C, Calmels B, Benech PD: The cleavage/polya-denylation activity tr igger ed by a U-rich motif sequence is differently required depending on the poly(A) site location at either the fir st or last 3′-terminal exon of the 2′-5′ oligo(A) synthetase gene. J Biol Chem 2002, 277:35808-35814.
25. Spiegel M, Pichlmair A, Muhlberger E, Haller O, Weber F: The anti-viral effect of interferon-beta against SARS-coronavir us is not mediated by MxA protein. J Clin Virol 2004, 30:211-213.
26. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G: Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 2004, 9:1003-1011.
27. Torisu H, Kusuhara K, Kira R, Bassuny WM, Sakai Y, Sanefuli M, Takemoto M, Hara T: Functional MxA promoter polymorphism associated with subacute sclerosing panencephalitis. Neurology 2004, 62:457-460.
28. Hijikata M, Mishiro, S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y: Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology 2001, 44:379-382.
29. Fernandez-Arcas N, Blanco A, Gaitan MJ, Nyqvist M, Alonso A, Reyes-Engel A: Differential transcriptional expresion of the polymorphic myxovirus resistance protein A in response to interferon-alpha treatment. Pharmacogenetics 2004, 14:189-193.